Igantibe

Human Hepatitis B Immunoglobulin, the active ingredient in Igantibe, is an immunoglobulin presented as a unspecified strength and dosage form for intramuscular use. It provides passive immunity to individuals at risk of hepatitis B virus infection, including post‑exposure prophylaxis and newborns of HBsAg‑positive mothers.

GNH USA supplies Igantibe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company ensures quality, regulatory compliance and reliable cold‑chain logistics for biologic products throughout the supply chain.

Igantibe, a human hepatitis B immunoglobulin, is used in the antiviral and hepatitis B prophylaxis therapeutic class. - Post‑exposure prophylaxis of hepatitis B: Provides immediate passive immunity to prevent infection after known exposure to hepatitis B virus. - Prevention of neonatal hepatitis B infection: Administered to newborns of HBsAg‑positive mothers to protect against perinatal transmission. - Protection of individuals with inadequate vaccine response: Supplies anti‑HBs antibodies to those who do not develop sufficient immunity after vaccination.

Human hepatitis B immunoglobulin may be associated with injection‑site reactions and systemic responses.

Common Side Effects: - Pain at injection site - Redness or swelling at injection site - Low‑grade fever - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Anaphylactic reaction - Severe urticaria - Serum sickness‑like illness - Acute hemolysis - Thrombotic events - Guillain‑Barré syndrome

When using Igantibe, several precautions should be observed to ensure safety and product integrity. - Assess hepatitis B immune status: Verify HBsAg and anti‑HBs levels before administration. - Monitor for allergic reactions: Observe patient for signs of hypersensitivity during and after injection. - Use only in approved indications: Restrict use to post‑exposure prophylaxis and neonatal protection as indicated. - Avoid in individuals with severe IgA deficiency: Increased risk of anaphylaxis has been reported. - Do not mix with other injectable products: Maintain sterility and avoid incompatibility. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Igantibe can interact with certain medicines or biological agents, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Live vaccines: Concurrent administration may diminish vaccine efficacy or increase adverse events. - Immunoglobulin products with different specificities: May cause immune complex formation.

Moderate Interactions (Monitor Closely): - Anticoagulants: Injection site bleeding risk may be heightened; monitor coagulation parameters. - Corticosteroids: May mask early signs of hypersensitivity; observe closely. - Immunosuppressive therapy: May alter clearance of administered antibodies; adjust monitoring.